saRNA SARS-CoV-2 vaccine

点击翻译按钮获取中文摘要

We will rapidly progress a synthetic vaccine against the novel Coronavirus into humanstudies within months. We have determined the genetic sequence (code) for the dominantsurface exposed protein of the virus, the key target for protective immune responses. Wehave modified this sequence to express a highly stabilised version of the protein,maximising its potential to evoke protective antibodies. We have used this modifiedsequence to generate a ribonucleic acid (RNA) based vaccine that can be amplified withincells following injection, maximising its expression. Our RNA vaccine delivers the geneticinstructions that tell muscles to make the viral surface protein which alerts the immunesystem to make protective antibodies. The advantage of our fully synthetic manufacturingprocess means that millions of doses can be made within weeks. This project will supportclinical grade manufacturing of our candidate vaccine, preclinical safety testing andhealthy volunteer studies to assess safety and immune potency of our vaccine. Shouldthis first phase be successful we would progress to wider clinical testing, including studiesto determine its protective effects against natural infection before making our vaccinewidely available.